GOLGA6B (Gene)

Organism:

Homo sapiens

Taxonomy (Entity type)

Synonyms:ENTREZ:55889, GOLGA, GOLGA6B, GOLGA6D, HGNC:32205, NM_018652, NP_061122, golgin A6 family member B

Id:296bf975-aa3d-5a37-b7e8-3096633473b7

Hgnc:HGNC:32205

Entrez:55889

Ensembl:ENSG00000215186

Description:golgin A6 family member B

This gene is found in a large, low copy repeat sequence or duplicon that is found in multiple copies, which are greater than 90% similar, on chromosome 15. Duplicons are associated with deletions, inversions and other chromosomal rearrangements that underlie genomic disease. This gene is a member of the golgin gene family, whose protein products localize to the Golgi apparatus. The majority of the related gene copies are thought to be transcribed pseudogenes. It is not known whether this gene is a pseudogene or if it encodes a golgin protein. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View GOLGA6B's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with GOLGA6B.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using GOLGA6B.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for GOLGA6B.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GOLGA6B.

Results found

Linked to

	Label	Description
	GSE145990 1 V 0 IBRUTINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 2 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 saha 6 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 saha 5 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE147876 GSE147877 enzalutamide MR42D 4 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE152699 GSE152723 vemurafenib 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 6 V 2 SAHA HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE161073 IDH1 inhibition 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 2 V 5 SULFORAPHANE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 5 V 2 SAHA HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

GSE145990 1 V 0 IBRUTINIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE48812 sulforaphane 2 v 5 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE77108 saha 6 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE77108 saha 5 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE147876 GSE147877 enzalutamide MR42D 4 v 7 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE152699 GSE152723 vemurafenib 3 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE77108 6 V 2 SAHA HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE161073 IDH1 inhibition 1 v 0 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE48812 2 V 5 SULFORAPHANE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE77108 5 V 2 SAHA HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.